- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05875714
Apremilast for Erythema Multiforme (AEM)
Apremilast for the Treatment of Refractory Erythema Multiforme
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Joshua S Bryer, BA
- Phone Number: 215-662-6597
- Email: jbryer@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Perelman Center for Advanced Medicine
-
Contact:
- Joshua Bryer, BA
- Phone Number: 215-662-6597
- Email: jbryer@pennmedicine.upenn.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
- Presence of oral, genital, or cutaneous erythema multiforme (EM) diagnosed or confirmed by a dermatologist based on clinical and/or histopathologic data.
- EM must be recurrent, defined as having =>2 flares in the six months prior to enrollment (or =>4 flares in the year prior to enrollment).
- EM must be refractory to standard therapy defined as 3-month treatment course with valacyclovir and/or a systemic immunomodulatory therapy such as colchicine, dapsone, azathioprine, mycophenolate mofetil, or methotrexate.
- Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).
- Willing and able to provide personally signed and dated informed consent form.
- Stated willingness and ability to comply with all study procedures including adhering to oral apremilast regimen and availability for the duration of the study.
- Adults aged 18-89 years old.
- People of childbearing potential (PCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, PCBP who engage in activity by which conception is possible must use one of the approved contraceptive options described below:
Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: External or internal condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
NOTE: This criterion is satisfied as "not applicable" (N/A) for those who practice abstinence as part of their usual and customary way of life, so long as this is maintained throughout study period plus 28 days post-treatment; are postmenopausal; or are of male sex/assigned male at birth (AMAB).
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
- Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinological, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
- Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if they were to participate in the study.
- Prior history of unmanaged depressive symptoms, suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
- A score of 4 or higher on Patient Health Questionnaire at screening.
- Pregnant or breast feeding.
- Active substance abuse or a history of substance abuse within 6 months prior to Screening.
Malignancy or history of malignancy, except for:
- treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;
- treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years.
- Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
- Prior treatment with apremilast.
- Patient unable to comply with study or conform to treatment diary or regular follow up visits.
- Patients with ocular EM.
- Concomitant use of immunosuppressive medications for treatment of other diseases.
- Patients with contraindications to Apremilast according to package insert.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EM flares on medication
Time Frame: 24 weeks
|
Change in frequency and duration of EM flares at 24-week evaluation.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain on medication
Time Frame: 24 weeks
|
Change in pain severity (on 0 to 10 scale) of EM flares at 24-week evaluation
|
24 weeks
|
Flares off medication
Time Frame: 36 weeks
|
Change in frequency and duration of flares at 36-week follow-up.
|
36 weeks
|
Pain off medication
Time Frame: 36 weeks
|
Change in pain severity (on 0-10 visual analogue scale) of EM flares at 36-week follow-up.
|
36 weeks
|
Prednisone
Time Frame: 36 weeks
|
Use of prednisone as rescue therapy to treat flares.
|
36 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert G Micheletti, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Vesiculobullous
- Skin Manifestations
- Erythema Multiforme
- Erythema
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 4 Inhibitors
- Apremilast
Other Study ID Numbers
- 842831
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erythema Multiforme
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingErythema Multiforme
-
Galderma R&DCompleted
-
Derm Research, PLLCCompletedPlaque PsoriasisUnited States
-
University Hospital, MontpellierCompleted
-
Case Comprehensive Cancer CenterCompletedStage IV Non-Small Cell Lung CancerUnited States
-
Kobe UniversityCompletedCoronary Artery Disease ProgressionJapan
-
The University of Texas Medical Branch, GalvestonCompletedProstate Cancer | Magnetic Resonance Imaging | Target Lesion | Fusion Biopsy | Clinically Significant Prostate Cancer | TransperinealUnited States
-
University of California, DavisWithdrawnToxic Epidermal NecrolysisUnited States
-
University of PernambucoCompleted
-
Brett KingSwedish Orphan BiovitrumTerminatedStevens-Johnson Syndrome | Toxic Epidermal NecrolysisUnited States
Clinical Trials on Apremilast
-
AmgenCompletedHealthy VolunteersUnited States
-
AmgenCompletedPsoriasis | Plaque-type PsoriasisUnited States, Canada
-
Diamant ThaciWithdrawnModerate to Severe Plaque PsoriasisGermany
-
University Hospitals Cleveland Medical CenterWithdrawn
-
AmgenCompletedPsoriatic ArthritisUnited States, Italy, Belgium, France, Canada, Taiwan, United Kingdom, Czechia, Russian Federation, Hungary, Germany, Bulgaria, Estonia, South Africa, Poland, Spain
-
AmgenCompletedPsoriatic ArthritisSpain, Canada, United States, Australia, Hungary, Poland, Austria, France, New Zealand, South Africa, Russian Federation, Germany, United Kingdom
-
Postgraduate Institute of Medical Education and...CompletedErythema Nodosum LeprosumIndia
-
Aga Khan UniversityWorld Health OrganizationCompletedPoliomyelitisPakistan
-
Jinnah Postgraduate Medical CentreCompleted
-
AmgenCompleted